We'll have to agree to disagree there - if you want to track the trajectory of the underlying business, especially when one-off non-cash expenses are being booked, EBIT is the only way to go.
"Competitor snapping at the heels"?? BEACON is a P2 study which only initiated this month so that compound is still 3-4 years away from approval, if it makes it at all.
CUV Price at posting:
$20.41 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)